Live data from Hacker News

Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

endpts.com

61–70 of 127 posts

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#61

Earlier quoted context omitted.

So more effective than antidepressants? Great news!

Do you have a source? I don't think it is "more effective" in terms of the remission rate. That being said, in this hypothetical world where you can choose between shrooms and SSRIs, you would have to compare the side effects as well.

21% delta in remission rate vs. placebo is higher than both SSRIs and bupropion in this study [0] for example (11% for both). This is also a single dose which is amazing.

[0] https://pubmed.ncbi.nlm.nih.gov/16086611/

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#62

The shrooms community has known about this for a long time, and now it's just about recreating the knowledge in peer-reviewed studies. Although there is a lot of "woo woo" on shrooms usage in the online communities, I do hope that researchers can extract the useful bits. This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot…

> This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot for how your "trip" (which we will now rebrand as "treatment") will go. This needs to be accounted for in future studies.

This is what I worry about. It's likely great, when done in the care of a licensed and trained therapist. It's not the mystical panacea many will make it out to be, and I worry that people will do it when they're not with the right people and it'll be a mess.

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#63

The shrooms community has known about this for a long time, and now it's just about recreating the knowledge in peer-reviewed studies. Although there is a lot of "woo woo" on shrooms usage in the online communities, I do hope that researchers can extract the useful bits. This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot…

Translating a dose in mg to the equivalent amount of dried mushrooms you would likely come across recreationally is quite difficult, but I believe 25mg equates to something like 4-5g of dried mushrooms which would be a full on trip beyond surfaces flowing like water :sweat-smile:

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#64
post #51

How does this get commercialized? I can't think of anything that's inherently cheap and easy to produce that you use for a few weeks and then never again that is also a financial cash cow the way most pharmaceuticals are. Disclaimer: I work for a pharma.

It's probably not "a few weeks and then never again" -- I'm not depressed, but anecdotes from people I know who've tried mushrooms at home for this suggest that one trip produces a noticeable improvement that fades over time.

It's possible that the full experience with a trained therapist who supervises the trip could produce longer-lasting changes, of course.

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#65

The shrooms community has known about this for a long time, and now it's just about recreating the knowledge in peer-reviewed studies. Although there is a lot of "woo woo" on shrooms usage in the online communities, I do hope that researchers can extract the useful bits. This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot…

Translating a dose in mg to the equivalent amount of dried mushrooms you would likely come across recreationally is quite difficult, but I believe 25mg equates to something like 4-5g of dried mushrooms which would be a full on trip beyond surfaces flowing like water :sweat-smile:

I did some brief googling on the topic earlier, and the best I could find was "anywhere from 5-20 milligrams of psilocybin per gram of dried mushroom". Which is very unhelpful for working out whether these people took a strong dose by recreational standards. :D

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#66

The shrooms community has known about this for a long time, and now it's just about recreating the knowledge in peer-reviewed studies. Although there is a lot of "woo woo" on shrooms usage in the online communities, I do hope that researchers can extract the useful bits. This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot…

> This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot for how your "trip" (which we will now rebrand as "treatment") will go. This needs to be accounted for in future studies. This is what I worry about. It's likely great, when done in the care of a licensed and trained therapist . It's not the mystical panacea many will m…

The Huberman Lab podcast episode on depression touches on this. According to Dr. Huberman the quality of the trip is not important, the chemical changes the brain function regardless.

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#67
As somebody who sometimes "treats" severe multi-decades-long depression with psychedelics, I'm not surprised that they'd have a positive impact but the news seems too unclear to my simple mind to make sense of a few things:

1- why is a private group on the stock market doing this, instead of public research & universities? vested interests in seizing a market of illegal drugs in a legal way worry me, because it's easy to completely forget the humans in the process when there's billions to be made

2- is 1mg declared a placebo with enough proof? I'm personally not receptive at all to any kind of "micro-dosing" but I've also seen equally anecdotal comments going exactly the opposite direction and loving that. Is there a study that thoroughly compares the 1mg dose to a fake product looking similar but with no psychoactive substance?

3- as someone keenly aware of an "afterglow" that can happen on psychedelics, I also don't see a proper discussion about (1) the potentially ephemeral nature of the benefits when taking a single dose, as well as (2) the difficulty of taking psychedelics along with pretty much any other treatment for mental health issues (SSRIs, MAOIs, anti-psychotics and so on, which all have their own counter-indications)

I very much love all the psychedelic experiences I've had in life, from simple doses to "heroic" and intensely crushing trips, and I've always tried to extract some long-term benefits from them during and post-trip, but even compared to a psychiatric treatment that doesn't help me quite enough (doesn't get rid of anhedonia, brain fog, suicidal ideation, etc etc), I have still come to see those trips as more of a targeted temporary relief for the soul that one should ideally leverage in the window of time post-trip - and not so much as an ongoing treatment in and of itself like what's offered by my meds.

At least from my limited perspective it hasn't been so much a treatment for a depression but a temporary relief from it, which offers a window of time to discuss anchoring constructive habits ("job search for an hour every morning", "clean up your house", ...) and having empathy for the self in pragmatic and measurable ways post-trip (cook yourself a meal, get a haircut, commit to physical activities again, etc). I'm not really convinced that we'll turn those substances into long-term treatments, but I could see them becoming a "shock therapy" of sorts.

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#68
post #66

Earlier quoted context omitted.

> This isn't like an SSRI. 25mg psilocybin isn't something you can just pop at the beginning of a workday. Your setting and "head space" matter a lot for how your "trip" (which we will now rebrand as "treatment") will go. This needs to be accounted for in future studies. This is what I worry about. It's likely great, when done in the care of a licensed and trained therapist . It's not the mystical panacea many will m…

The Huberman Lab podcast episode on depression touches on this. According to Dr. Huberman the quality of the trip is not important, the chemical changes the brain function regardless.

But is it solely the chemical changes in the brain that "fix" the depression, or does it also have to do with integrating what you've seen and experienced into your worldview?

Re: Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms

#70
post #67

As somebody who sometimes "treats" severe multi-decades-long depression with psychedelics, I'm not surprised that they'd have a positive impact but the news seems too unclear to my simple mind to make sense of a few things: 1- why is a private group on the stock market doing this, instead of public research & universities? vested interests in seizing a market of illegal drugs in a legal way worry me, because it's eas…

I guess the hope is, by figuring out how it helps, the effect can be prolonged?
Post reply on HN